Evidence map›Paper›PMID 29417289›Full record

ArticleWorld journal of urology2018

Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries.

Tim Nestler, Johannes Huber, Adrienne M Laury, Hendrik Isbarn, Axel Heidenreich, Hans U Schmelz, Christian G Ruf

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Tim NestlerDepartment of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany. tim-nestler@web.de.ORCID http://orcid.org/0000-0001-6033-6364
Johannes HuberDepartment of Urology, University Hospital Dresden, Dresden, Germany.
Adrienne M LauryDepartment of Otolaryngology-Head and Neck Surgery, San Antonio Uniformed Services Health Education Consortium (SAUSHEC), Fort Sam Houston, Texas, USA.
Hendrik IsbarnMartini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Axel HeidenreichDepartment of Urology, University Hospital Cologne, Cologne, Germany.
Hans U SchmelzDepartment of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany.
Christian G RufDepartment of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany.
Bundeswehrzentralkrankenhaus Koblenz · DEFederal Office of Bundeswehr Equipment, Information Technology and In-Service Support · DESan Antonio Uniformed Services Health Education Consortium · USUniversität Hamburg · DEUniversity Hospital Cologne · DE

Funding

Bundesministerium der Verteidigung 07K1-S-141316
6 · The paper itself

Abstract

purposeDue to the excellent cure rates for testicular cancer (TC), focus has shifted towards decreasing therapy-related morbidities. Thrombosis is a frequent complication of cisplatin chemotherapy. Furthermore, the optimal route of administration for chemotherapy is still under debate. The purpose of this study was to assess the patterns of care concerning dosing and duration of thromboprophylaxis currently utilized in TC patients in German-speaking countries as well as the route of chemotherapy administration.

methodsA standardized questionnaire was sent to all members of the German TC Study Group (GTCSG) and to all the urological university hospitals in Germany. The questionnaire was also sent to the oncologic clinics at those universities where urologists do not administer chemotherapy.

resultsThe response rate was 87% (55/63). Prophylactic anticoagulation with low-molecular-weight heparin (LMWH) was administered in 94% of the clinics. The dosing of LMWH was prophylactic (85%), high prophylactic (adjusted to bodyweight) (7%), or risk adapted (9%). After completion of chemotherapy, anticoagulation was continued in 15 clinics (33%) for 2 to 24 weeks, while the remainder stopped the LMWH upon cessation of chemotherapy. Chemotherapy was administered via central venous access in 59%, peripheral IV in 27%, or both in 14% of the clinics.

conclusionsMost of the institutions performed some form of thromboprophylaxis, although the modes of application varied by institution type and amongst the urologists and oncologists. Prospective studies are needed to evaluate the incidence, date of occurrence, and risk factors of venous thrombosis during TC chemotherapy to provide a recommendation concerning prophylactic anticoagulation.

Indexed as

AnticoagulantsAustriaGermanyHealth Care SurveysHeparin, Low-Molecular-WeightHumansMaleProspective StudiesSwitzerlandTesticular NeoplasmsVenous ThrombosisAnticoagulantsHeparin, Low-Molecular-WeightChemotherapyGerm cell cancerTesticular cancerThromboprophylaxisVenous accessVenous thrombosis

Identifiers

PMID29417289
OpenAlexW2786205640

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.